Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma

Ítems similars

• Octogenarians with EGFR-mutated non-small cell lung cancer treated by tyrosine-kinase inhibitor: a multicentric real-world study assessing tolerance and efficacy (OCTOMUT study)
  per: Corre, Romain, et al.
  Publicat: (2018)
• Impact of Programmed Death Ligand 1 Expression in Advanced Non-Small–Cell Lung Cancer Patients, Treated by Chemotherapy (GFPC 06-2015 Study)
  per: Auliac, Jean-Bernard, et al.
  Publicat: (2020)
• PD-L1-expression patterns in large-cell neuroendocrine carcinoma of the lung: potential implications for use of immunotherapy in these patients: the GFPC 03-2017 “EPNEC” study
  per: Arpin, Dominique, et al.
  Publicat: (2020)
• Phase III randomized study of carboplatin pemetrexed with or without bevacizumab with initial versus “at progression” cerebral radiotherapy in advanced non squamous non-small cell lung cancer with asymptomatic brain metastasis
  per: Monnet, Isabelle, et al.
  Publicat: (2021)
• Duration of nivolumab for pretreated, advanced non–small‐cell lung cancer
  per: Margaux Geier, et al.
  Publicat: (2020-10-01)